These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 24518603

  • 1. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X.
    Br J Cancer; 2014 Mar 04; 110(5):1169-78. PubMed ID: 24518603
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J, Choi Y, Ko YS, Kim Y, Pyo JS, Jang BG, Kim MA, Lee JS, Chang MS, Park JW, Lee BL.
    Cancer Res Treat; 2018 Jan 04; 50(1):239-254. PubMed ID: 28343375
    [Abstract] [Full Text] [Related]

  • 4. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
    Yu Y, Yu X, Liu H, Song Q, Yang Y.
    Int J Mol Med; 2018 Aug 04; 42(2):998-1007. PubMed ID: 29786108
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY, Jung K, Song JY, Kim S, Shin S, Kwon YJ, Oh E, Park WY, Song SY, Choi YL.
    BMC Cancer; 2017 Aug 10; 17(1):535. PubMed ID: 28806950
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, Li W, Li J.
    Oncotarget; 2015 Feb 10; 6(4):2009-22. PubMed ID: 25576915
    [Abstract] [Full Text] [Related]

  • 14. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.
    Clin Cancer Res; 2013 May 01; 19(9):2572-83. PubMed ID: 23493349
    [Abstract] [Full Text] [Related]

  • 15. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.
    Int J Cancer; 2015 Apr 01; 136(7):1629-35. PubMed ID: 25157953
    [Abstract] [Full Text] [Related]

  • 16. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A.
    Gastric Cancer; 2015 Apr 01; 18(2):227-38. PubMed ID: 24626858
    [Abstract] [Full Text] [Related]

  • 17. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
    Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K.
    Biochem Biophys Res Commun; 2011 Apr 01; 407(1):219-24. PubMed ID: 21377448
    [Abstract] [Full Text] [Related]

  • 18. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
    Yang Y, Wu N, Shen J, Teixido C, Sun X, Lin Z, Qian X, Zou Z, Guan W, Yu L, Rosell R, Liu B, Wei J.
    Gastric Cancer; 2016 Jul 01; 19(3):778-88. PubMed ID: 26404902
    [Abstract] [Full Text] [Related]

  • 19. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z, Wang J, Ji D, Wang C, Liu R, Wu Z, Liu L, Zhu D, Chang J, Geng R, Xiong L, Fang Q, Li J.
    Clin Cancer Res; 2014 Sep 01; 20(17):4559-73. PubMed ID: 24973425
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.